Table 3.
Mapping of statistically significant predictors of local or distant tumor control.
| Outcome (N) | Patient factors | % | Tumor factors | % | Treatment factors | % | % of reports with no significant predictor |
|---|---|---|---|---|---|---|---|
| LOCAL CONTROL (outcomes: disease free survival, disease progression, failure free survival, local failure, local progression free survival, local or disease recurrence, nodal failure, non-local relapse free survival, primary tumor control, time to progression, tumor growth, or tumor shrinkage) | |||||||
| 181 | 49 | ||||||
| Age | 6 | Date (staging after PET scan introduction) | < 1 | Booster field size | < 1 | ||
| Blood marker (neutrophil/lymphocyte ratio) | < 1 | Histology (SCC or lymphovascular invasion) | 7 | Chemotherapy | 12 | ||
| Gender | 9 | Imaging (texture) | 2 | Contouring | 2 | ||
| Lung function | < 1 | PET data | 8 | Field size | < 1 | ||
| Medication | < 1 | PTV | < 1 | Fractionation | 3 | ||
| Molecular markers (e.g., AI, Bcl-2, COX2, EGFR, FasL, FGF-2, HER-2, MMP-2, p53, SPARC expression, Rb, trace elements, VEGF, etc.) | 7 | Stage | 34 | RT technique | 5 | ||
| Performance status | 17 | Tissue(clinical vs. pathological diagnosis) | < 1 | ||||
| Smoking | 2 | Total tumor volume | 2 | ||||
| Symptoms | 1 | Tumor site | 3 | ||||
| Weight loss | 4 | ||||||
| DISTANT CONTROL (outcomes: metastatic disease-free survival, distant metastasis, or distant failure) | |||||||
| 72 | 46 | ||||||
| Age | 6 | Histology (SCC, lymphovascular invasion, or tumor grade) | 11 | Chemotherapy | 3 | ||
| Blood marker (platelet-to-lymphocyte ratio) | 1 | PET data | 8 | Contouring | 1 | ||
| Comorbidity | 4 | Stage | 24 | Fractionation | 4 | ||
| Gender | 8 | Total tumor volume | 1 | RT Technique | 1 | ||
| Medication | 1 | Tumor site | 4 | ||||
| Molecular markers (e.g., SNP, apoptotic index, index based on CRP, albumin, etc.) | 7 | ||||||
| Performance status | 15 | ||||||
| Weight loss | 6 | ||||||
| BRAIN METASTASIS | |||||||
| 8 | 50 | ||||||
| Age | 25 | Histology (SCC or tumor grade) | 38 | Chemo | 13 | ||
| Molecular marker (neuron-specific enolase or CA125) | 25 | Tumor marker | 13 | ||||
| Performance status | 13 | ||||||
Identical study reports may be counted for more than one predictor therefore total percentage may not be equal to 100.
AI, Apoptotic index; EGFR, epidermal growth factor receptor; FGF-2, fibroblast growth factor-2; HER-2, human epidermal growth factor receptor-2; MMP-2, matrix metalloproteinase; Rb, retinoblastoma protein; VEGF, vascular endothelial growth factor; SCC, squamous cell carcinoma; PTV, planning target volume; RT, radiotherapy.